Wire · operational-macro
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
Fractyl Health is focusing its resources on advancing Revita for FDA De Novo submission in late Q4 2026, following positive pivotal trial results in post-GLP-1 weight maintenance, while discontinuing its Rejuva gene therapy program and reducing workforce by 45% to extend cash runway into Q2 2027.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to focus your clinical resources sharply when a lead product nears FDA submission and trial success. Fractyl's move shows that cutting side projects and tightening spend is key to survive the costly late-stage approval run.
◆ Coverage
1 source · 22 Oct 2026
◆ Related on Wire
◆ Topics